Amyotrophic Lateral Sclerosis Treatment Market size to grow by USD 663.7 million from 2023 to 2028, North America to account for 42% of market growth – Technavio

NEW YORK, Dec. 7, 2023 /PRNewswire/ — The amyotrophic lateral sclerosis treatment market is expected to grow by USD 663.7 million from 2023 to 2028. In addition, the momentum of the market will progress at a CAGR of  12.79% during the forecast period, according to Technavio Research. The market is segmented by Type (Intravenous and Oral), Distribution Channel (Hospital pharmacies, Retail pharmacies, and Online pharmacies), and Geography (North America, Europe, Asia, and Rest of World (ROW)). North America is estimated to account for 42% of the global market growth during the forecast period. Due to prominent companies like Pfizer, Sangamo Therapeutics, and Celgene, the US leads the North American market for amyotrophic lateral sclerosis (ALS). 

This report offers an up-to-date analysis of the current market scenario, the latest trends and drivers, and the overall market environment. Read a PDF Free Sample Report

Company Profile:

AB Science SA, Alkem Laboratories Ltd., Apotex Inc., Aquestive Therapeutics Inc., Biogen Inc., Brainstorm Cell Therapeutics Inc., CORESTEM Inc., Cytokinetics Inc., Denali Therapeutics Inc., Dr Reddys Laboratories Ltd., Eledon Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Italfarmaco Holding SPA, Medindia Health, Mitsubishi Chemical Group Corp., Otsuka Holdings Co. Ltd., Revalesio Corp., Sanofi, Sun Pharmaceutical Industries Ltd., and Treeway BV

Denali Therapeutics Inc.: The company offers amyotrophic lateral sclerosis treatment that aims to slow disease progression, including advancing clinical trials of investigational eIF2B activator treatment DNL343.

   To gain access to more vendor profiles available with Technavio, buy the report!

The market share growth by the intravenous segment will be significant during the forecast period. One of the major growth factors of this market is the boost in the majority of amyotrophic lateral sclerosis. 

Learn about the contribution of each segment summarized in concise infographics and thorough descriptions. View a PDF Free Sample Report

“Besides analyzing the current market scenario, our report examines historic data from 2018 to 2022”- Technavio

Amyotrophic Lateral Sclerosis Treatment Market: Driver & Trend:

An increase in the incidence and prevalence of amyotrophic lateral sclerosis is notably driving the market growth. The incidence of amyotrophic lateral sclerosis (ALS), commonly known as Lou Gehrig’s disease, is on the rise. ALS is a progressive and fatal neuromuscular condition with no cure presently available.

An increase in the aging population is an emerging trend shaping the market growth. 

Strategic alliances among market vendors are a key trend in the amyotrophic lateral sclerosis treatment market. Identify key trends, drivers, and challenges in the market. Download a sample report to gain access to this information.

What are the key data covered in this amyotrophic lateral sclerosis treatment market report?

CAGR of the market during the forecast periodDetailed information on factors that will drive the growth of the amyotrophic lateral sclerosis treatment market between 2023 and 2028.Precise estimation of the amyotrophic lateral sclerosis treatment market size and its contribution to the market in focus on the parent marketAccurate predictions about upcoming trends and changes in consumer behaviorGrowth of the amyotrophic lateral sclerosis treatment market across North America, Europe, Asia, and ROWA thorough analysis of the market’s competitive landscape and detailed information about vendorsComprehensive analysis of factors that will challenge the growth of amyotrophic lateral sclerosis treatment market vendors.

Related Reports:

The global neuromuscular disease therapeutics market size is estimated to grow by USD 6,513.28 million at a CAGR of 10.3% between 2022 and 2027.  

The scleroderma therapeutics market share is expected to increase by USD 573.87 million from 2021 to 2026, and the market’s growth momentum will accelerate at a CAGR of 5.44%.

ToC:

Executive Summary

Market Landscape

Market Sizing

Historic Market Sizes

Five Forces Analysis

Market Segmentation by Type 

Market Segmentation by Distribution Channel

Market Segmentation by Geography

Customer Landscape

Geographic Landscape

Drivers, Challenges, & Trends

Company Landscape

Company Analysis

Appendix

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/amyotrophic-lateral-sclerosis-treatment-market-size-to-grow-by-usd-663-7-million-from-2023-to-2028–north-america-to-account-for-42-of-market-growth—technavio-302008658.html

SOURCE Technavio